Eversource Energy Faces Regulatory Backlash as Sell-Off Exposes Widening Expectation Gap

The market's recent optimism for Eversource Energy has been sharply reset. Just weeks after a bullish upgrade, Wells Fargo has cut its price target to $63 from $79 and downgraded its rating from Overweight to Equal Weight. This move frames a classic "sell the news" dynamic, where a prior positive catalyst failed to hold up against subsequent reality.

The immediate trigger was a regulatory stunner. The Public Utilities Regulatory Authority of Connecticut delivered a 4-0 vote against the approval of Eversource's planned sale of Aquarion Water. This outcome was unexpected and definitively halted a transaction that had been a source of optimism. The denial directly undermines a potential asset monetization and a path to bolster the balance sheet, forcing a reassessment of near-term value.

This reset is part of a broader trend of regulatory headwinds. Just days earlier, BMO Capital had also lowered its target to $75, citing a 100 basis point reduction in the base return on equity (ROE) by the Federal Energy Regulatory Commission. That change directly pressures the utility's earnings power and valuation, adding to the pressure on the stock.

The stock's reaction is textbook. Shares have sold off, with the stock down nearly 9% over the past week. This drop shows how the market repriced the stock once the positive narrative of a smooth Aquarion sale and favorable regulatory shifts was shattered. The Wells Fargo cut crystallizes that shift, moving from a bullish stance to a neutral one as the expectation gap between prior optimism and current regulatory friction has widened.

What Wasn't Priced In: The Regulatory Backlash

The Wells Fargo cut wasn't just a change of opinion; it was a response to specific, unexpected events that shattered a recent positive narrative. The market had been pricing in a smoother regulatory path, but two definitive setbacks have reset expectations.

First was the outright denial of the Aquarion Water sale. After weeks of growing optimism that Connecticut's regulatory atmosphere had improved, the Public Utilities Regulatory Authority delivered a 4-0 vote against approval. This wasn't a delay or a condition; it was a definitive halt to a potential asset monetization and a key growth catalyst many had expected to close. The transaction's demise was a surprise that wasn't reflected in the stock's recent valuation.

Second, and more structurally damaging, was the Federal Energy Regulatory Commission's order. FERC resolved a long-standing issue by reducing the base return on equity (ROE) by 100 basis points, setting the new rate at 9.57%. This change directly pressures the utility's earnings power and valuation. As BMO Capital noted, the shift represents approximately 20 cents of ROE exposure across the forecast period. This wasn't a whisper number; it was a concrete, negative regulatory decision that alters the fundamental economics of the business.

The expectation gap was wide. Just weeks before these events, analyst upgrades were flowing. Wells Fargo itself had upgraded the stock to Overweight just days before, and other firms like BofA had raised targets. The market had priced in that optimism. The subsequent regulatory backlash-first a denied sale, then a mandated ROE cut-created a sharp reality check. The stock's nearly 9% drop over the past week shows how the market repriced the stock once these specific, negative catalysts materialized. What was priced in was a favorable regulatory wind; what arrived was a headwind.

The Guidance Reset and Valuation Gap

The market's reset is now fully reflected in management's own outlook. Eversource's guidance for 2026 is a clear signal of a lower growth trajectory. The company projects earnings per share in the range of $4.80 to $4.95, with CFO John Moreira explicitly stating that growth in the year will be limited largely due to regulatory timing factors. This is a direct response to the recent setbacks, acknowledging that the positive catalysts of a smooth Aquarion sale and favorable regulatory shifts are no longer in play.

This creates a valuation gap. The stock trades at a discount to the average analyst target of $75.61, but those targets are now anchored to a materially lower earnings path. The new price targets from firms like BMO and Wells Fargo, at $75 and $63 respectively, reflect this reset. The key question for investors is whether the current price adequately discounts the slower growth through 2026 and the heightened regulatory uncertainty.

The path to closing that gap lies in future regulatory decisions. Management's expectation for earnings growth to pick up in 2027 and 2028 is explicitly tied to improved outcomes on two fronts: the recovery of storm-related costs and adjustments in distribution rates. These are the specific catalysts that will drive the company's five-year EPS growth target of 5% to 7%. Until these regulatory approvals are secured, the stock's multiple will likely remain under pressure, as the market waits for the reality of higher earnings to catch up with the new, more modest guidance.